Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.
Post-COVID neuroinflammation has emerged as a persistent challenge, with patients reporting brain fog, memory lapses, and slowed cognitive processing months after acute infection. Researchers are now examining peptide combinations that might address the underlying neuroimmune dysregulation. Among these, Thymosin Alpha-1 (a 28-amino acid thymic peptide) and Pinealon (a short tripeptide, Glu-Asp-Arg) have drawn attention for their potential to modulate inflammation and support neuronal resilience. This article surveys the evidence and outlines a stack design that also incorporates GHK-Cu (a copper-binding tripeptide) for tissue repair and, where relevant, Hexarelin (a growth hormone secretagogue) for neuroprotection.
Discovery and early characterization
Thymosin Alpha-1 was first isolated from calf thymus tissue in the 1970s and later synthesized for research into immune modulation (Goldstein 1977). Early studies focused on its role in T-cell maturation and its ability to restore immune competence in immunodeficient models. Pinealon emerged from Russian biogerontology research in the 1990s, where investigators screened short peptides for neuroprotective effects (Khavinson 2003). Its sequence, derived from a conserved region of the brain protein epithalamin, was found to influence gene expression related to neuronal survival. GHK-Cu was discovered in human plasma in 1973 as a factor that binds copper and promotes wound healing (Pickart 1973). Hexarelin, a synthetic hexapeptide, was developed in the 1990s as a more stable analog of GHRP-6, with potent growth hormone-releasing properties (Deghenghi 1994).
Early research era: immune and neural foundations
Initial work on Thymosin Alpha-1 centered on its immunomodulatory actions. It was shown to enhance natural killer cell activity and promote the differentiation of regulatory T cells, suggesting a capacity to rebalance immune responses rather than simply stimulate them (Romani 2006). This dual action, dampening harmful inflammation while supporting protective immunity, later became relevant to post-viral syndromes. Pinealon's early research demonstrated its ability to protect neurons from oxidative stress and to improve cognitive function in aged animal models (Khavinson 2005). The peptide appeared to penetrate the blood-brain barrier and accumulate in brain regions critical for memory. GHK-Cu was studied extensively for its ability to attract immune cells, stimulate collagen synthesis, and modulate metalloproteinases, making it a candidate for tissue remodeling after injury (Pickart 2008). Hexarelin was investigated primarily for its growth hormone-releasing effects, but researchers noted that it also bound to the CD36 receptor in the brain, reducing neuronal death after ischemic injury (Muccioli 2000).
Modern research era: post-COVID neuroinflammation insights
The COVID-19 pandemic shifted attention to peptides that could address the prolonged neuroinflammatory state seen in many survivors. Neuroinflammation after SARS-CoV-2 infection involves microglial activation, elevated cytokines like IL-6 and TNF-alpha, and disruption of the blood-brain barrier (Theoharides 2021). Thymosin Alpha-1 has been studied in clinical trials for COVID-19 itself, where it reduced mortality and lowered inflammatory markers, likely by restoring T-cell function and suppressing cytokine storms (Matteucci 2020). These findings prompted interest in its use for post-acute sequelae, where a smoldering inflammatory process may persist. Pinealon has not been tested directly in COVID-19 cohorts, but its mechanisms align with the need to calm microglial reactivity and support neuronal repair. In vitro, Pinealon reduced the expression of pro-inflammatory genes in glial cells exposed to lipopolysaccharide, a model of neuroinflammation (Khavinson 2018).
GHK-Cu has gained attention for its ability to reset gene expression toward a healthier state, a property termed "genomic reprogramming" (Pickart 2015). In the context of neuroinflammation, it may suppress TGF-beta-induced scarring and promote the clearance of damaged proteins. Stacking GHK-Cu with Hexarelin for injury recovery has been explored for musculoskeletal healing, but the neuroprotective overlap is notable. Hexarelin's affinity for the CD36 receptor in the brain provides a direct anti-inflammatory pathway, as CD36 activation on microglia can shift them from a pro-inflammatory to a phagocytic, debris-clearing phenotype (Muccioli 2015). This mechanism could complement Thymosin Alpha-1's systemic immune modulation.
Current research trajectory: stack design and synergy
Designing a peptide stack for post-COVID neuroinflammation requires balancing immune modulation, neuroprotection, and tissue repair. No single peptide addresses all these facets. The combination of Thymosin Alpha-1 and Pinealon forms a core duo: Thymosin Alpha-1 works systemically to restore immune balance, while Pinealon targets the brain directly to reduce neuroinflammation and support cognitive function. Adding GHK-Cu provides a regenerative component, potentially aiding in the repair of subtle neuronal damage and restoring the extracellular matrix. Hexarelin can be incorporated for its neuroprotective effects, but its growth hormone-releasing action may be less desirable in some individuals, so its inclusion depends on specific goals.
Typical research protocols for Thymosin Alpha-1 involve subcutaneous doses of 1.0 to 1.6 mg two to three times weekly, often in cycles of four to six weeks. Pinealon is used at 5 to 10 mg daily, either subcutaneously or intranasally, for periods of 20 to 30 days. GHK-Cu is commonly administered at 1 to 2 mg daily, and Hexarelin at 100 to 200 mcg two to three times daily, though the latter is often cycled to avoid desensitization. These are not clinical guidelines but reflect patterns in published studies and investigator-led protocols.
Key considerations for stack design include:
- Immune modulation first: Thymosin Alpha-1 may be initiated before other peptides to establish a more regulated immune environment, reducing the risk of excessive inflammation when neuroactive peptides are introduced.
- Timing of neuroactive peptides: Pinealon and Hexarelin can be started concurrently or shortly after Thymosin Alpha-1, with Pinealon given in the morning to align with circadian rhythms of neuronal repair.
- GHK-Cu for sustained repair: This peptide is often used later in a protocol or continuously at low doses, as its effects on gene expression are cumulative.
- Monitoring markers: In research settings, tracking cytokines like IL-6 and TNF-alpha, along with cognitive assessments, can help gauge the stack's impact.
Synergy may arise from overlapping pathways. Thymosin Alpha-1 and Pinealon both influence NF-kB signaling, a master regulator of inflammation, but through different mechanisms. GHK-Cu and Hexarelin both interact with copper metabolism and growth factor pathways, potentially amplifying tissue repair. However, careful dosing is essential to avoid overstimulation, particularly with Hexarelin, which can elevate cortisol if used excessively.
What comes next: emerging evidence and refined protocols
Ongoing research is likely to clarify the role of these peptides in post-viral syndromes. Clinical trials of Thymosin Alpha-1 for long COVID are in early stages, with endpoints including cognitive function and fatigue scores. Pinealon is being studied in models of chronic neuroinflammation, with preliminary data suggesting it can restore synaptic plasticity after prolonged immune challenge. The combination of GHK-Cu with neuroprotective peptides is an area of active investigation, particularly for conditions involving both inflammation and degeneration.
Future stack designs may incorporate additional peptides like PT-141 (a melanocortin agonist) for its anti-inflammatory effects in the brain, or Oxytocin for its ability to reduce microglial activation. However, these additions require more evidence before they can be recommended even in research contexts. The current trajectory points toward personalized protocols based on biomarker profiles, with Thymosin Alpha-1 and Pinealon serving as a foundational pair.
As the peptide field matures, researchers are also exploring delivery methods that enhance brain penetration, such as intranasal formulations of Pinealon and GHK-Cu. These approaches could increase efficacy while reducing systemic exposure. The intersection of immunology and neuroscience in post-COVID care will likely drive innovation in peptide therapeutics for years to come.
Common questions
How do Thymosin Alpha-1 and Pinealon differ in their anti-inflammatory actions?
Thymosin Alpha-1 primarily modulates the adaptive immune system, enhancing regulatory T-cell function and restoring the balance between pro- and anti-inflammatory cytokines. It acts systemically and has a long history of use in immune dysregulation. Pinealon, in contrast, appears to work directly on neural cells, reducing the expression of inflammatory genes in microglia and astrocytes. Its effects are more localized to the central nervous system, making it a complementary agent for neuroinflammation rather than a substitute for systemic immune modulation.
Can GHK-Cu be combined with Thymosin Alpha-1 and Pinealon safely?
In research settings, GHK-Cu has been combined with both peptides without reported antagonism. GHK-Cu's primary role is tissue remodeling and gene regulation, which does not interfere with immune modulation. However, because GHK-Cu can influence copper-dependent enzymes, monitoring copper status is advisable in long protocols. The combination is often used sequentially, with Thymosin Alpha-1 and Pinealon initiated first to address inflammation, followed by GHK-Cu for repair.
What is the rationale for including Hexarelin in a neuroinflammation stack?
Hexarelin offers two potential benefits: neuroprotection via the CD36 receptor and increased growth hormone secretion, which may support neuronal repair. Its neuroprotective effects are independent of its endocrine actions, so even low doses that do not significantly elevate growth hormone can reduce brain inflammation. However, its use is more experimental, and it may not be suitable for all protocols due to its effects on appetite and cortisol.
Are there any risks of over-suppressing the immune system with Thymosin Alpha-1?
Thymosin Alpha-1 is considered an immunomodulator rather than an immunosuppressant. It tends to normalize immune function, enhancing weak responses and calming excessive ones. In studies, it has not been associated with increased infection risk. Nevertheless, in the context of post-COVID neuroinflammation, the goal is to reduce pathological inflammation without impairing antiviral immunity, and Thymosin Alpha-1's mechanism aligns with this objective.